000284091 001__ 284091
000284091 005__ 20260126111935.0
000284091 0247_ $$2doi$$a10.1093/ajh/hpw053
000284091 0247_ $$2ISSN$$a0895-7061
000284091 0247_ $$2ISSN$$a1879-1905
000284091 0247_ $$2ISSN$$a1941-7225
000284091 037__ $$aDZNE-2026-00099
000284091 041__ $$aEnglish
000284091 082__ $$a610
000284091 1001_ $$aPerucci, Luiza O.$$b0
000284091 245__ $$aLipoxin A4 Is Increased in the Plasma of Preeclamptic Women
000284091 260__ $$aOxford$$bOxford Univ. Press$$c2016
000284091 3367_ $$2DRIVER$$aarticle
000284091 3367_ $$2DataCite$$aOutput Types/Journal article
000284091 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769422735_1864
000284091 3367_ $$2BibTeX$$aARTICLE
000284091 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284091 3367_ $$00$$2EndNote$$aJournal Article
000284091 520__ $$aExcessive inflammation is involved in preeclampsia (PE) pathogenesis. Lipoxin A4 (LXA4) is an eicosanoid that counter-regulates inflammation. The main objective of this study was to determine LXA4 plasma levels in PE women. The correlations among LXA4 levels, ultrasensitive C-reactive protein (us-CRP) levels, and clinical/laboratory parameters of the studied participants were also investigated.LXA4 plasma levels were determined by ELISA in 23 nonpregnant, 26 normotensive pregnant, and 27 PE women (early PE (N = 10) and late PE (N = 17)), according to gestational age (GA) at clinical symptoms onset). The clinical/laboratory parameters included in Spearman's correlation analysis were: systolic and diastolic blood pressure (SBP and DBP, respectively), lactate dehydrogenase (LDH) activity, platelet count, proteinuria, and white blood cell count (WBC).LXA4 levels were higher in PE women than in nonpregnant and normotensive pregnant women, and similar between nonpregnant and normotensive pregnant women. LXA4 plasma levels were higher in early PE vs. normotensive pregnancy (GA < 34 weeks) and in late PE vs. normotensive pregnancy (GA ≥ 34 weeks). No significant differences were detected between early and late PE. LXA4 levels were positively correlated with us-CRP levels, SBP, DBP, and WBC. No significant correlation was detected between LXA4 levels and the other laboratory parameters.Chronic inflammation in PE, in spite of increased levels of LXA4, points to a possible failure in this regulatory pathway. Further studies are necessary to clarify this issue and to evaluate the role of LXA4 and other proresolving mediators of inflammation in the pathogenesis of PE.
000284091 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000284091 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000284091 650_7 $$2Other$$ablood pressure
000284091 650_7 $$2Other$$ahypertension
000284091 650_7 $$2Other$$ainflammation
000284091 650_7 $$2Other$$alipoxin A4
000284091 650_7 $$2Other$$apreeclampsia
000284091 650_7 $$2Other$$aresolution.
000284091 650_7 $$2NLM Chemicals$$aLipoxins
000284091 650_7 $$2NLM Chemicals$$alipoxin A4
000284091 650_7 $$09007-41-4$$2NLM Chemicals$$aC-Reactive Protein
000284091 650_2 $$2MeSH$$aAdult
000284091 650_2 $$2MeSH$$aC-Reactive Protein: metabolism
000284091 650_2 $$2MeSH$$aCase-Control Studies
000284091 650_2 $$2MeSH$$aFemale
000284091 650_2 $$2MeSH$$aHumans
000284091 650_2 $$2MeSH$$aLipoxins: blood
000284091 650_2 $$2MeSH$$aPre-Eclampsia: blood
000284091 650_2 $$2MeSH$$aPre-Eclampsia: immunology
000284091 650_2 $$2MeSH$$aPregnancy
000284091 650_2 $$2MeSH$$aYoung Adult
000284091 7001_ $$0P:(DE-2719)9003461$$aCampi Santos, Patricia$$b1$$udzne
000284091 7001_ $$0P:(DE-2719)9001782$$aSecchim Ribeiro, Lucas$$b2$$udzne
000284091 7001_ $$aSouza, Danielle G.$$b3
000284091 7001_ $$aGomes, Karina B.$$b4
000284091 7001_ $$aDusse, Luci M. S.$$b5
000284091 7001_ $$aSousa, Lirlândia P.$$b6
000284091 773__ $$0PERI:(DE-600)1479505-X$$a10.1093/ajh/hpw053$$gVol. 29, no. 10, p. 1179 - 1185$$n10$$p1179 - 1185$$tAmerican journal of hypertension$$v29$$x0895-7061$$y2016
000284091 8564_ $$uhttps://pub.dzne.de/record/284091/files/DZNE-2026-00099_Restricted.pdf
000284091 8564_ $$uhttps://pub.dzne.de/record/284091/files/DZNE-2026-00099_Restricted.pdf?subformat=pdfa$$xpdfa
000284091 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003461$$aExternal Institute$$b1$$kExtern
000284091 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001782$$aExternal Institute$$b2$$kExtern
000284091 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000284091 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-07$$wger
000284091 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J HYPERTENS : 2022$$d2025-01-07
000284091 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000284091 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000284091 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000284091 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000284091 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000284091 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000284091 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000284091 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000284091 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000284091 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000284091 920__ $$lyes
000284091 980__ $$ajournal
000284091 980__ $$aI:(DE-2719)1040260
000284091 9801_ $$aEXTERN4VITA